Scinopharm Taiwan, Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 06, 2019 at 05:44 pm EST
Share
ScinoPharm Taiwan, Ltd. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced sales was TWD 683.613 million compared to TWD 817.705 million a year ago. Operating income was TWD 30.766 million compared to TWD 123.014 million a year ago. Net income was TWD 32.209 million compared to TWD 82.606 million a year ago. Basic earnings per share was TWD 0.04 compared to TWD 0.1 a year ago. For the nine months, sales was TWD 2,073.231 million compared to TWD 2,664.599 million a year ago. Operating income was TWD 209.786 million compared to TWD 404.317 million a year ago. Net income was TWD 167.809 million compared to TWD 349.206 million a year ago. Basic earnings per share was TWD 0.21 compared to TWD 0.44 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
